Frontage wholly-owned subsidiary Frontage Laboratories has completed the purchase of clinical Phase I-IIa business, Frontage Clinical Services, in the US.
Located in Secaucus, New Jersey, Frontage Clinical Services is experienced in executing comprehensive Phase I-IIa studies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It offers a complete suite of services from study design to the delivery of final reports including study design, protocol and ICF generation, IRB submission, clinical study execution, clinical pharmacology, BE/BA studies, data and project management, programming and statistical analysis, and medical writing.
The company’s team works closely with clients for developing a unique approach to overcome the study challenges, while eliminating risk and increasing efficiency.
It uses best practices in study design and execution for advancing investigative compounds to drug candidates.
The company provides comprehensive services in drug metabolism and pharmacokinetics (DMPK), formulation development, analytical testing, bioanalysis, preclinical safety and toxicology and early phase clinical studies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFrontage stated that the purchase allows investments in the future and improve its existing capabilities as well as service offerings.
It will also help in the expansion into new study areas, such as studies in specialty patient populations.
Frontage CEO and chairman Dr Song Li said: “Frontage has been actively expanding service offerings in drug discovery and development. This acquisition is part of service expansion efforts.
“The integration of Frontage Clinical into the Frontage family will speed up the expansion of Frontage’s services into clinical trials, providing the capability to support our clients’ drug development programs beyond safety & toxicology studies and into early phase clinical trials and late phase patient studies.”
